Back to News
Market Impact: 0.25
Kamada Confirms KedRAB Supply As U.S. Rabies Exposures Increase
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Kamada confirmed it has sufficient KedRAB inventory and manufacturing capacity to meet increased U.S. demand following the CDC's September 10, 2026 health advisory. The update indicates supply readiness for the rabies immune globulin product and could support near-term demand, although no sales or financial guidance was provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
KMDA0.58
More News
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
- US to Sell F-35s to Saudi Arabia in $24.3 Billion Deal
- Crusoe raises $3.9B to build massive data centers and small modular “AI factories”
- Jensen Huang says Nvidia will sell twice as many chips next year
- Generac shares surge on big Amazon deal. Wall Street thinks the generator stock has more to go
- UK Lawmakers Say Thames Creditors Have Been Joyriding Family Car